Lilly's Verzenio has been approved to treat HR+, HER2-, node-positive, high risk early breast cancer.

Be sure to talk to your healthcare provider about Verzenio and how to take it. Your healthcare provider is the best person to help you decide if Verzenio is right for you. Verzenio® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

Oncology Pipeline Loxo@Lilly aims to create medicines that make life better for all those affected by cancer around the world. Bringing together the focus and spirit of a biotech with the scale, resources, and heritage of Lilly, our team is focused on rapidly delivering impactful new medicines for people with cancer.

Jaypirca's approval is based on data from a subset of 120 patients in an early-to-mid stage trial that showed half of them responded to the drug, while 13% achieved a complete response. The trial assessed the efficacy of 200 mg dose of the drug until disease progression or unacceptable toxicity.

Basaglar, Glyxambi, Jardiance, Jentadueto, Jentadueto XR, Synjardy, Synjardy XR, Tradjenta and Trijardy XR are part of the Boehringer Ingelheim–Lilly Alliance.

The new drug, elacestrant, addresses a significant unmet need. It is the first and only treatment approved specifically to fight breast cancers with mutations in an estrogen receptor called ESR1, which make breast cancers resistant to standard endocrine therapy.

Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6.

On March 3, 2023, the FDA approved abemaciclib (brand name Verzenio) with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, early breast cancer at high risk of recurrence.

Lilly was founded in 1876 by Colonel Eli Lilly, a man committed to creating high-quality medicines that met real needs in an era of unreliable elixirs peddled by questionable characters. His charge to the generations of employees who have followed was this: "Take what you find here and make it better and better."

In the original lawsuit, people who paid out-of-pocket for Lilly's insulin Humalog accused the company, plus Sanofi and Novo Nordisk, of inflating the drug's list price while offering steep discounts to pharma middlemen who determine what drugs are available through insurance plans.

Lilly introduced Iletin ® (animal-source insulin, Lilly), the world's first commercially available insulin product, for the treatment of diabetes – then a fatal disease with no effective treatment options.

Today Lilly is known best for clinical depression drugs Prozac (1986) and Cymbalta (2004) and antipsychotic medication Zyprexa (1996), though its biggest revenue drivers are diabetes drugs Trulicity (2014) and Humalog (1996).